Study Shows HK L-137 Reduces Inflammation in Healthy Overweight Individuals — Takes Front Line Against Metabolic Syndrome
There’s a reason why the health-conscious focus has turned toward foods, supplements and behaviors to reduce inflammation. It’s why House Wellness Foods has put decades of meticulous research into the anti-inflammatory benefits of its unique immunobiotic Lactobacillus plantarum HK L-137, the primary ingredient of its Immuno-LP20®. A just-published study illuminates how this bacillus, in its nonviable form, can be especially important, even lifesaving, to those contending with obesity.
Inflammation is a bodily response we rely on to counter stress, infection and external toxins. But we know that it is also one of the keystones of metabolic dysfunction. Many have gone as far as to suggest that inflammation is the defining characteristic of all infirmity, including the depredating aspects of the aging process itself, leading to eventual organ failure. Unchecked, it can cause the decline of overall health, is linked to a string of metabolic complications, and implicated in dozens of autoimmune diseases from lupus to MS.
Notably, even otherwise healthy individuals under the stress associated with high body mass can suffer a rapidly deteriorating downward spiral; and as we know, obesity is among the most prevalent disease factors in post-industrial society worldwide, (affecting about 40 percent of the U.S. population alone). Simply put, production of inflammatory cytokines increases in individuals carrying more body fat. Though the popular literature avoids the harsh details, the manifestation of this destructive cycle includes insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, hypertension, and dyslipidemia.
The new study from House Wellness Foods laboratories, in cooperation with the Medical Institute of Bioregulation, Kyushu University, describes in detail the process by which inflammation sets its destructive effects in motion. Adipose tissue produces an abundance of inflammatory cytokines, resulting in elevated serum levels of inflammatory mediators (C-reactive protein and leukocyte concentration among them). Tumor necrosis factor and interleukin induce systemic insulin resistance and affect lipid metabolism. There is a concomitant elevation of the serum levels of triglycerides and very-low-density lipoprotein (VLDL).
In the inflammation response, cells communicate via extraordinarily complex means to protect muscles and organs in bodies subjected to ordinary stress or injury. The research paper defines the consequences of lingering inflammation, such as that associated with overweight, and how the inflammatory mediators present in obese or overweight persons need to be suppressed to thwart associated metabolic disorders such as insulin resistance and hyperlipidemia.
Lactic acid-based bacterial probiotics have long shown effectiveness in immune modulation and lipid metabolism. Viable lactobacilli in foods like kefir and other probiotic boosters have proved valuable in lowering total cholesterol levels, but their effect is limited both by their chemistry and the mechanisms by which they act on the body. Multiple peer-reviewed studies have shown that nonviable bacilli, like (heat-killed) HK L-137, are equally, and in many instances more effective in improving obesity-induced inflammation and abnormalities of lipid metabolism, with a more profound impact on immune response as gauged by multiple measurements including enhanced Th1-related immune functions, such as concanavalin A (Con A)-induced proliferation in T cell production.
Heat-killing’s advantage is that it strengthens the bacterial organism’s cellular barriers and fixes its biogenetic material. It stands up to gastric fluids and remains intact through to the ileum of the small intestine, to go on to spur immune response in the mucosa. Heat-killing is what gives HK L-137, the prime constituent of House’s Immuno-LP20, its character as an immunobiotic, and as multiple peer-reviewed studies show, its cell protective and regenerative function supports quality of life improvements that include dramatic reduction of upper respiratory infection and periodontal disease. It also makes HK L-137 available for the widest range of applications due to its ability to withstand processing. Nonviability gives it an unparalleled shelf life without diminishing its effectiveness.
House Wellness Foods has devoted nearly 30 years to both the clinical study of the immunological and protective properties of HK L-137, and the refinement of its natural, food product-based production. The apex of its efforts is Immuno-LP20®, its functional immunobiotic based on HK L-137.
Metabolic syndrome is a crisis of global proportion. Countering it, House Wellness Foods, in its supplements and functional food products, has concentrated its focus on supporting the body’s innate ability to bolster immunity and restore vitality at the cellular level. It is a quest for nothing less than the sustenance of superior health and vigor, and the extension of all life on the planet.
House Wellness Foods Corp.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GPD Companies, Inc. to Acquire Distrupol22.1.2021 16:33:00 EET | Press release
GPD Companies, Inc., an affiliate of One Rock Capital Partners, LLC (“One Rock”), today announced that it has entered into a definitive agreement to acquire Distrupol, a subsidiary of Univar Solutions Inc. (NYSE: UNVR) and a leading European distributor of thermoplastics to the polymer processing industry. Terms of the transaction, which is expected to close in the first half of 2021, were not disclosed. Headquartered in Surrey, England, with broad geographic reach across Europe, Distrupol has provided value-added sales and application development of thermoplastic resins for over 50 years. Through its decades-long relationships with world class supply partners, the company offers a robust array of superior performance products and solutions that meet the needs of diverse end users from leading and emerging industries, such as the consumer, medical, automotive, and electrical sectors, among others. Distrupol caters to over 1,300 customers across 13 countries with a portfolio of over 4,0
Schlumberger Announces Fourth-Quarter and Full-Year 2020 Results22.1.2021 14:50:00 EET | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the fourth-quarter and full-year 2020. Fourth-Quarter Results (Stated in millions, except per share amounts) Three Months Ended Change Dec. 31, 2020 Sept. 30, 2020 Dec. 31, 2019 Sequential Year-on-year Revenue $5,532 $5,258 $8,228 5% -33% Income (loss) before taxes - GAAP basis $471 $(54) $452 n/m 4% Net income (loss) - GAAP basis $374 $(82) $333 n/m 12% Diluted EPS (loss per share) - GAAP basis $0.27 $(0.06) $0.24 n/m 12% Adjusted EBITDA* $1,112 $1,018 $1,648 9% -33% Adjusted EBITDA margin* 20.1% 19.4% 20.0% 73 bps 6 bps Pretax segment operating income* $654 $575 $1,006 14% -35% Pretax segment operating margin* 11.8% 10.9% 12.2% 90 bps -40 bps Net income, excluding charges & credits* $309 $228 $545 35% -43% Diluted EPS, excluding charges & credits* $0.22 $0.16 $0.39 37% -44% Revenue by Geography International $4,343 $4,210 $5,834 3% -26% North America 1,167 1,034 2,339 13% -50% Other 22 14 55 n/m n/m $5,532 $5,258 $8,228 5% -
JEOL: Release of a New Cold Field Emission Cryo-Electron Microscope CRYO ARM™ 300 II (JEM-3300)22.1.2021 09:00:00 EET | Press release
JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new cold field emission cryo-electron microscope (cryo-EM), the CRYO ARM™ 300 II (JEM-3300), to be released in January 2021. This new cryo-EM has been developed based on the concept of "Quick and easy to operate and get high-contrast and high-resolution images". This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005316/en/ Cold Field Emission Cryo-Electron Microscope CRYO ARM(TM) 300 II (JEM-3300) (Photo: Business Wire) Development Background Recent dramatic improvement of resolution in single particle analysis (SPA) using cryo-EM has led to SPA as an essential method for structural analysis of proteins. To address this market, JEOL released the CRYO ARM™ 300 in 2017. Equipped with a cold field emission gun (Cold FEG) for enhanced resolution and a cryo-stage for loading multiple samples, the CRYO ARM™ 300 has continued to achieve best-in-class res
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment22.1.2021 01:12:00 EET | Press release
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines — ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine — dosed once monthly, as an option to replace the current antiretroviral (ARV) regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]) on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy.1 Lynn Baxter, Head of North America, ViiV H
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)22.1.2021 00:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its Biologics License Application (BLA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The BLA submission is based on data from the Phase 2 POD1UM-202 trial evaluating retifanlimab in previously treated patients with locally advanced or metastatic SCAC who have progressed on, or are intolerant of, standard platinum-based chemotherapy. The trial enrolled 94 patients, including several with well-controlled human immunodeficiency virus (HIV) infection. The study, which was recently presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, resulted in an objective response rate (ORR) of 14% for retifanlimab monotherapy as determined by inde
Wistron and Kalray Announce FURIO1200™ Storage Appliance21.1.2021 19:45:00 EET | Press release
Wistron, a leader in ICT (Information and communications technology) products, and Kalray (Paris:ALKAL) (Euronext Growth Paris: ALKAL), a leading provider in new generation of processors specialized in Intelligent Data Processing from Cloud to Edge, announce the availability of FURIO1200™, a 24-Flash-Drive NVMe-oF based storage node appliance, integrating Kalray’s NVMe-oF K200™ smart storage adapter, powered by its MPPA® Coolidge™ intelligent processor, and Wistron LYMMA chassis. FURIO1200™ is a new type of hyper-fast disaggregated storage solution delivering ultra-high throughput and reliability. It is the ideal solution for Cloud Service Providers and Enterprises running applications with intensive AI and Data Analytics workloads as well as to optimize their next generation storage. Data Centers are undergoing a very important revolution due to the explosion of usages, the surge of data to be processed and the exponential growth of the number of machines to be managed to support this
NumAlim Selects Dawex and Orange Business Services for its Data and Services Exchange Platform21.1.2021 19:40:00 EET | Press release
NumAlim announced an agreement with Dawex, the leader in Data Exchange technology, and Orange Business Services, a network-native digital services company, to deploy its agri-food digital exchange platform. By relying on these two leading players, NumAlim chose secure technological solutions guaranteeing the sovereignty of French food data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005722/en/ (Photo: Dawex) As early as Q1 2021, the NumAlim data and services exchange "Hub" will offer 18,000 companies in the food industry the opportunity to valorize, acquire and enrich all types of data: production, consumption, traceability, consumer opinions and research, as well as a wide range of services based on data (trend analysis, reformulation, regulatory watch…). "NumAlim is the answer to the needs for transparency, value creation and trust expressed by the food industry, consumers, and public authorities.” says Jérôme Fr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom